Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLRG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLRG1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View KLRG1 Products |
| Gene Delivery | KLRG1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for flow cytometry validation. |
View KLRG1 Products |
| Benchmark Ab | Anti-KLRG1 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences (e.g., ABBV-151 analog). |
View KLRG1 Products |
| Validator | KLRG1 siRNA Set For target knockdown verification in primary T/NK cells. |
View KLRG1 Products |
| Related Target A | E-Cadherin (CDH1) Primary inhibitory ligand for KLRG1; critical for setting up ligand-blocking assays. |
View E-Cadherin Products |
| Related Target B | N-Cadherin (CDH2) Alternative low-affinity ligand; vital for selectivity and cross-reactivity profiling. |
View N-Cadherin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand-blocking screening (E-Cadherin interaction) | Human E-Cadherin and KLRG1 proteins are HEK293-expressed, ensuring native post-translational glycosylation required for physiological binding. |
| Cross-species ortholog validation (Cyno/Mouse) | Cynomolgus and Mouse KLRG1 recombinant proteins are sequence-verified and purity-tested via SDS-PAGE (>95%). |
| Lack of positive control benchmarks | Sequence-active clinical benchmark biosimilar antibodies are available for assay baseline standardization. |
| High-background assay noise | Endotoxin-controlled formulations (<1.0 EU/μg) prevent non-specific immune cell activation in primary cell assays. |
Live KLRG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLRG1 therapeutics is intensifying, with major players shifting focus from traditional monotherapies to combination regimens targeting immune checkpoint resistance. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of T-cell and NK-cell senescence in immunologically "cold" tumors. KLRG1, as a co-inhibitory receptor marker of senescent but highly cytotoxic effector cells, represents a critical node in overcoming resistance to standard anti-PD-1/PD-L1 therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | AbbVie (ABBV-151) | Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Ligand-blocking Assay (Need high-purity KLRG1 ECD-Fc & E-Cadherin) |
| Bispecific Antibody (e.g., PD-1 x KLRG1) | Biotech Innovators | Refractory Solid Tumors | Dual-binding verification (Need high-purity human PD-1 and KLRG1 proteins) |
| NK Cell Therapy Enhancers | Academic & Clinical Consortia | Hematological Malignancies, Solid Tumors | Stable KLRG1 expression validation (Need KLRG1 Lentiviral Particles) |